advertisement
BioSante initiated with "market outperform"
11/09/09 - Rodman & Renshaw
NEW YORK, November 9 (newratings.com) - Analysts at Rodman & Renshaw initiate coverage of Biosante Pharmaceuticals Inc (BPAX) with a "market outperform" rating. The target price is set to $4.
Share Recommend this article to a friend
add BPAX to my stocks and get e-mail alerts on BioSante Pharmaceuticals
News